Program
disitamab vedotin
Also written as “RC48-ADC”, “Disitamab Vedotin” and “Disitamab Vedotin Injection”.
In Pfizer's pipeline, HER2-directed antibody-drug conjugate
. Its studies are mostly in Stomach Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell · Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 3022 open or running | phase 3since Apr 8, 2018 | Aug 20, 2016 | Dec 2026phase 3 · NCT06221748 |
| Pfizer | 55 open or running | phase 3since Jun 9, 2023 | Apr 19, 2021 | Dec 11, 2026phase 2 · NCT04879329 |
| Jiangsu HengRui Medicine | 11 open or running | phase 2since Apr 26, 2024 | Apr 26, 2024 | Dec 31, 2031phase 2 · NCT06417554 |
- Named in Pfizer’s own pipeline as
disitamab vedotin PF-08046051
, phase 3, as of Nov 3, 2026 (source).
Also a collaborator on its studies: Merck.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseSeagen licensed it from RemeGen, for everywhere outside Asia, and in Japan and Singapore.Announced Aug 9, 2021 · Source: Seagen and RemeGen (release), Aug 9, 2021
- AcquisitionPfizer acquired Seagen, and with it the rights Seagen held.Completed Dec 14, 2023 · Source: Pfizer (release), Dec 14, 2023
How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Aug 20, 2016.
- Jun 9, 2023Phase 3 study in Carcinoma, Transitional CellPfizer · NCT05911295 · 412 enrolled · United States, Argentina, Australia and more
- Jul 1, 2023Phase 3 study in Stomach NeoplasmsRemeGen · NCT05980481 · 201 enrolled · China
- Aug 15, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT06003231 · 120 enrolled · United States, Australia, Canada and more
- Aug 18, 2023Phase 2 study in Solid TumorRemeGen · NCT06016062 · 221 planned · China
- Nov 23, 20232 phase 2 studiesRemeGen · NCT06155396, NCT06155383
- Nov 27, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06157892 · 54 enrolled · United States, Australia, Canada and more
- Dec 3, 2023Phase 2 study in Breast NeoplasmsRemeGen · NCT06178159 · 40 planned · China
- Jan 15, 2024Phase 3 study in Stomach NeoplasmsRemeGen · NCT06221748 · 90 planned · China
- Jan 17, 20242 phase 2 studiesRemeGen · NCT06227156, NCT06227117
- Apr 12, 2024Phase 2 study in High-risk Non-muscle Invasive Bladder CancerRemeGen · NCT06378242 · 24 planned · China
- Apr 26, 2024Jiangsu HengRui Medicine's first study: phase 2 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06417554 · 80 planned · China
- Apr 17, 2025Phase 3 study in Stomach NeoplasmsRemeGen · NCT06944496 · 616 planned · China
- May 9, 2025Phase 2 study in Breast NeoplasmsPfizer · NCT06966453 · 74 enrolled · United States, Australia, Brazil and more
- Dec 3, 2025Phase 3 study in Stomach NeoplasmsRemeGen · NCT07315750 · 555 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Stomach NeoplasmsRemeGen · NCT06221748
- Dec 11, 2026Primary completion: phase 2 study in Carcinoma, Transitional CellPfizer · NCT04879329
- Dec 31, 2026Primary completion: phase 3 study in Carcinoma, Transitional CellRemeGen · NCT05302284
- Jan 29, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellPfizer · NCT05911295
TargetBeta
“HER2-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via the protease-cleavable linker maleimidocaproyl-valine-…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07315750Stomach Neoplasms · China | 3 | Recruiting | RemeGen | Jun 30, 2029 | 555 |
| NCT06966453Breast Neoplasms · United States, Australia, Brazil and more | 2 | Active, not recruiting | Pfizer | Oct 25, 2027 | 74 |
| NCT06944496Stomach Neoplasms · China | 3 | Not yet recruiting | RemeGen | May 15, 2028 | 616 |
| NCT06417554Advanced Solid Tumors · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2031 | 80 |
| NCT06378242High-risk Non-muscle Invasive Bladder Cancer · China | 2 | Recruiting | RemeGen | Mar 15, 2029 | 24 |
| NCT06227156Castration-resistant Prostate Cancer · China | 2 | Recruiting | RemeGen | Dec 2025 | 40 |
| NCT06227117Breast Neoplasms · China | 2 | Recruiting | RemeGen | Dec 2025 | 120 |
| NCT06221748Stomach Neoplasms · China | 3 | Recruiting | RemeGen | Dec 2026 | 90 |
| NCT06178159Breast Neoplasms · China | 2 | Recruiting | RemeGen | Jun 2026 | 40 |
| NCT06157892Breast Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Pfizer | Jul 28, 2029 | 54 |
| NCT06155396Uterine Cervical Neoplasms · China | 2 | Recruiting | RemeGen | Jun 30, 2027 | 116 |
| NCT06155383Stomach Neoplasms · China | 2 | Recruiting | RemeGen | Jan 31, 2025 | 90 |
| NCT06016062Solid Tumor · China | 2 | Recruiting | RemeGen | Dec 31, 2025 | 221 |
| NCT06003231Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Active, not recruiting | Pfizer | Mar 27, 2026 | 120 |
| NCT05980481Stomach Neoplasms · China | 3 | Active, not recruiting | RemeGen | Jul 10, 2025 | 201 |
| NCT05911295Carcinoma, Transitional Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Jan 29, 2027 | 412 |
| NCT05940896Solid Tumor · China | 1 | Recruiting | RemeGen | Nov 16, 2024 | 24 |
| NCT05943379Non-Muscle Invasive Bladder Neoplasms · China | 2 | Recruiting | RemeGen | Dec 1, 2025 | 85 |
| NCT05745740Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | RemeGen | Dec 1, 2027 | 26 |
| NCT05302284Carcinoma, Transitional Cell · China | 3 | Recruiting | RemeGen | Dec 31, 2026 | 452 |
| NCT05297552Muscle Invasive Bladder Carcinoma · China | 2 | Recruiting | RemeGen | Jun 1, 2024 | 40 |
| NCT05135715Melanoma · China | 2 | Recruiting | RemeGen | Dec 30, 2024 | 50 |
| NCT04965519Gynecological Malignancy · China | 2 | Recruiting | RemeGen | Oct 2024 | 120 |
| NCT04879329Carcinoma, Transitional Cell · United States, Argentina, Australia and more | 2 | Recruiting | Pfizer | Dec 11, 2026 | 372 |
| NCT04714190Stomach Neoplasms · China | 3 | Recruiting | RemeGen | Dec 1, 2024 | 351 |
| NCT04400695Breast Neoplasms · China | 3 | Recruiting | RemeGen | Dec 31, 2027 | 366 |
| NCT04329429Biliary Tract Neoplasms · China | 2 | Active, not recruiting | RemeGen | Nov 3, 2023 | 57 |
| NCT04311034Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | RemeGen | Dec 21, 2021 | 37 |
| NCT04073602Carcinoma, Transitional Cell · China | 2 | Completed | RemeGen | Sep 30, 2022 | 19 |
| NCT03809013Carcinoma, Transitional Cell · China | 2 | Completed | RemeGen | Mar 4, 2021 | 64 |
| NCT03556345Stomach Neoplasms · China | 2 | Completed | RemeGen | Jun 1, 2020 | 127 |
| NCT03507166Carcinoma, Transitional Cell · China | 2 | Completed | RemeGen | Oct 29, 2018 | 43 |
| NCT03500380Breast Neoplasms · China | 3 | Active, not recruiting | RemeGen | Jul 31, 2024 | 301 |
| NCT03052634Advanced Breast Cancer · China | 2 | Completed | RemeGen | Jul 31, 2022 | 112 |
| NCT02881190Solid Tumors · China | 1 | Completed | RemeGen | Jun 27, 2019 | 57 |
| NCT02881138Solid Tumors · China | 1 | Completed | RemeGen | Apr 30, 2020 | 24 |
How it is read
Names in the registry
- “RC48-ADC”, 15 entries
- “disitamab vedotin”, 4 entries
- “Disitamab Vedotin”, 3 entries
- “Disitamab Vedotin Injection”, 3 entries
- “Disitamab vedotin”, 2 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 7 studies
- Breast Neoplasms, 6 studies
- Carcinoma, Transitional Cell, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Non-Muscle Invasive Bladder Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.